Introduction
TGF-b is a multifunctional growth factor whose bestknown function is to inhibit cell growth and suppress tumor formation (Massague et al., 2000) . Loss of TGFb growth inhibition is one of the most common cellular events in the pathogenesis of numerous types of human cancers. TGF-b causes cells to accumulate in mid-to-late G1 phase of the cell cycle by blocking the transition from G1 to S (Laiho et al., 1990) . TGF-b signals through two types of cell surface receptors (type I and type II receptors). TGF-b binds to the type II receptor directly. Ligand-associated type II receptors recruit type I receptors into a complex. Both the type I and type II TGF-b receptors are Ser/Thr kinases; the ligand-bound type II receptor phosphorylates the type I receptor in its GS domain and activates its kinase activity. Activated type I receptors relay the TGF-b signal by phosphorylating the intracellular substrates Smad2 and Smad3. After Smad2 and Smad3 are phosphorylated, they form a complex with Smad4, a common partner involved in the signaling of many TGF-b-related cytokines. The Smad2/3/4 complex moves to the nucleus and functionally collaborates with distinct transcription factors to turn on or off transcription of many TGF-b-responsive genes that regulate cell proliferation (Attisano and Wrana, 2002) .
Cell cycle progression through the G1/S transition requires activation of the Cdk2-cyclin E complex; this enzyme phosphorylates the retinoblastoma (Rb) protein to allow the passage of the cell past the G1 restriction point. This activates transcription of histone and other genes necessary for DNA replication and allows entry into the S phase (Sherr and Roberts, 1999) .
TGF-b inhibits the Cdk2-cyclin E activity via at least two pathways. First, TGF-b can activate transcription of two inhibitors of cyclin-dependent protein kinases, p21
Cip1 and p15 INK4B (Hannon and Beach, 1994; Datto et al., 1995) . A surge in the level of p15 INK4B displaces p27
Kip1 from the complex of Cyclin D/Cdk4/6 and the resulting p27
Kip1 binds to the Cdk2-cyclin E complex (Reynisdottir and Massague, 1997) . This inactivates its kinase activity and blocks cell cycle progression (Reynisdottir et al., 1995; Reynisdottir and Massague, 1997) . TGF-b also represses transcription of the protooncogene c-myc (Pietenpol et al., 1990) . Myc can induce transcription of cdc25A (Galaktionov et al., 1996) , a phosphatase that causes dephosphorylation of Cdk2. This is a necessary step for cdk2 kinase activation (Sherr and Roberts, 1999) . Indeed, TGF-b decreases the level of cdc25A phosphatase as a means of repressing cell cycle progression in cells that fail to turn on p15 in response to TGF-b (Iavarone and Massague, 1997) . Therefore, TGF-b controls cell cycle progression by directly regulating cell cycle inhibitors and cell cycle activators via transcriptional and post-transcriptional mechanisms.
The Cdk2-cyclin E kinase is activated upon removal of p27
Kip1 by accelerated proteolysis of this cell cycle inhibitor or dissociation of p27
Kip1 from the Cdk2-cyclin E complex due to a competitive association with Cdk4/6 complex (Sherr and Roberts, 1999) . Sequestering of p27 Kip1 can be achieved by regulating its subcellular localization. It has been shown that alterations of p27 Kip1 subcellular localization are correlated with acquisition of TGF-b resistance phenotypes in cells treated with hepatocyte growth factor (HGF) or cells transformed by ras oncogene (Tsubari et al., 1999; Liu et al., 2000c) . In human breast cancer cells, phosphorylation of p27 on Ser-152 by Akt blocks the nuclear import of p27 and sequester it away from its nuclear targets (Blain and Massague, 2002; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . The abundance of cell cycle inhibitor p27
Kip1 is regulated predominantly by posttranslational mechanisms mediated by proteolysis (Nakayama et al., 2001) . The SCF ubiquitination machinery present in some E3 ubiquitin ligases is a major proteolysis apparatus that controls cell cycle transitions through selective degradation of cell cycle regulators. The SCF ubiquitin-protein ligases are composed of four proteins: Skp1, Cullin, F-box-containing substrate receptor, and the recently identified ring domain proteins ROC1/Rbx1p/Hrt1p (Deshaies, 1999; Harper, 2001) . These multimeric protein complexes can be separated into two functional entities: the F-boxcontaining substrate receptor is responsible for substrate recruitment, and the remaining subunits, Cullin, Skp1 and Roc1, form a core complex that mediates ubiquitin transfer to the substrate (Harper, 2001) .
Skp2 is a F-box-containing substrate receptor that mediates cell cycle-dependent ubiquitilation of p27 Kip1 and target it to degradation by the proteasome Sutterluty et al., 1999; Tsvetkov et al., 1999; Winston et al., 1999) . Skp2 was originally identified as a protein that binds the S phase promoting kinase Cdk2 and a neutralizing antibody against Skp2 blocks G1/S transition (Zhang et al., 1995) . Subsequent studies showed that Skp2 is part of the SCF complex that ubiquitinates p27
Kip1 resulting in its destruction (Lisztwan et al., 1998; Lyapina et al., 1998; Michel and Xiong, 1998) . Overexpression of Skp2 in serum-starved rodent fibroblasts induces p27
Kip1 degradation (Sutterluty et al., 1999) . Although Skp2 is important for p27
Kip1 degradation, recombinant Skp2 is not sufficient for p27 Kip1 
ubiquitination. Efficient degradation of p27
Kip1 requires the presence of Cks1, which enhances the interaction between Skp2 and p27
Kip1 (Ganoth et al., 2001; Spruck et al., 2001; Sitry et al., 2002) .
Expression of Skp2 is cell cycle dependent with low levels of expression in G0 and M phase and high levels during the S/G2 phase of the cell cycle (Lisztwan et al., 1998; Michel and Xiong, 1998) . It has been shown that Skp2 is degraded by the proteasome in G0/G1 and stabilized when cells enter the cell cycle (Wirbelauer et al., 2000) . Rapid degradation of Skp2 is F-box independent and CUL-1 dependent. It has been proposed that autocatalytic Skp2 ubiquitination and destruction is one of the mechanisms to limit the F-box protein abundance during G0/G1 phase of the cell cycle (Zhou and Howley, 1998; Deshaies, 1999; Galan and Peter, 1999) . It is not clear whether this mechanism is also utilized to stop cell proliferation when cells are challenged with negative growth factors such as TGF-b.
We show here that treatment of epithelial cells with TGF-b results in a decrease of Skp2 protein abundance with a concomitant increase in the stability of p27 Kip1 during the G1 phase of the cell cycle. Downregulation of Skp2 by TGF-b is likely due to a post-translational mechanism that involves proteasome-dependent degradation of Skp2. Using a cell-free degradation system, we demonstrate that TGF-b-induced Skp2 degradation requires the activity of the ubiquitin conjugating enzyme Cdc34. Finally, transcription of Cks1, which has been shown to be required for p27
Kip1 ubiquitination, is also repressed by TGF-b. Downregulation of Cks1 may contribute to destabilization of Skp2. In the absence of Cks1 and phosphorylated p27 Kip1 , Skp2 can undergo autoubiquitination and be targeted to degradation. Our data suggest that the TGF-b signal transduction pathway inhibits the SCF Skp2 E3 ubiquitin ligase activity through regulating Skp2 and Cks1. This regulation could be an important molecular mechanism for the growth inhibitory effect of TGF-b on epithelial cells.
Results

TGF-b enhances the stability of p27
kip1 during G1/S transition Proliferation of mink lung epithelial cells MuLv1 (CCL64) can be tightly regulated by TGF-b. TGF-b causes cells to accumulate at the G1 phase of the cell cycle (Laiho et al., 1990) . TGF-b treatment results in a stable association between p27
Kip1 and the Cdk2-cyclin E complex (Koff et al., 1993; Reynisdottir et al., 1995). p27 Kip1 has been shown to be ubiquitinated by the SCF E3 ubiquitin ligase and targeted to proteasome degradation as cells undergo the G1/S transition Sutterluty et al., 1999) . Since p27
Kip1 accumulates in the Cdk2-cyclin E complex in cells treated with TGFb, we asked whether TGF-b signaling affects the stability of p27
Kip1 during the G1/S transition. To measure the stability of p27
Kip1 in cells exposed to TGF-b vs untreated cells, a pulse-chase experiment using [ 35 S]methionine was performed. As shown in Figure 1a , the half-life of p27 Kip1 in cells not exposed to TGF-b after release into growth medium is 2 h. In contrast, the half-life of p27
Kip1 is more than 4 h in cells treated with TGF-b for 12 h. We have also measured p27
Kip1 stability using a cycloheximide chase experiments (Figure 1b ). Cells treated with or without TGF-b were incubated with cycloheximide for the indicated times. The amounts of p27
Kip1 accumulated in cells were measured by immunoblotting. The half-life of p27 Kip1 measured in this assay correlates well with the pulse chase analysis using [
35 S]methionine ( Figure 1a ). These data suggest that TGF-b signaling increases the stability of p27
Kip1 to ensure that excess amounts of p27 Kip1 bind the Cdk2-cyclin E complex inhibiting cell cycle progression.
Tgf-b treatment decreases the steady-state levels of Skp2
The abundance of p27 Kip1 is regulated predominantly by the ubiquitin-mediated proteasome pathway (Pagano et al., 1995) . Degradation of p27
Kip1 is mediated by the SCF Skp2 E3 ubiquitin ligase complex Sutterluty et al., 1999) . Thus, increased stability of p27
Kip1 could be a result of deficiency in the E3 activity or of inhibition of p27 Kip1 binding to the E3 ligase complex. To distinguish between these possibilities, we measured the steady-state levels of Skp2, an essential component of the SCF complex that has been shown to be responsible for p27
Kip1 recognition transition Sutterluty et al., 1999) . MvLu1 cells were synchronized in G0/G1 by density-induced contact inhibition by maintaining them at confluent density for 2 weeks (Laiho et al., 1990) . Cells synchronously move through the cell cycle upon release into fresh growth media. FACS analysis indicates that the doubling time for this cell line is 21 h. The G1 to S transition begins approximately 12 h after release (Laiho et al., 1990) . As shown in Figure 2a , without TGF-b treatment the levels of Skp2 protein are regulated during cell cycle progression. Skp2 is low in G0/G1 and accumulates rapidly at the onset of S phase ( Figure 2a , lanes 2, 4, 6 and 8). However, in the presence of TGF-b, very little accumulation of Skp2 is observed (Figure 2a , lanes 1,3, 5 and 7). The levels of p27 Kip1 were also measured by immunoblotting. Between 12 and 16 h, which is approximately the period when cells undergo G1 to S transition, p27
Kip1 levels remain elevated and Skp2 stays very low in cells treated with TGF-b. The reverse is true for cells that are treated without TGF-b (Figure 2a , lanes 1 vs 2 and 3 vs 4). After G1 to S transition, p27 Kip1 levels remain steady even in the cells that are not exposed to TGF-b. These data suggest that one of the important components of the E3 ubiquitin ligase (SCF Skp2 ) is downregulated in the presence of TGF-b.
Post-translational regulation of the steady-state levels of Skp2 by TGF-b
The observed decreased in levels of Skp2 by TGF-b could be due to a transcriptional effect or a posttranscriptional effect. To distinguish between these two possibilities, we first attempted to measure the steadystate levels of Skp2 mRNA by Northern analysis. As shown in Figure 2b , Skp2 mRNA levels showed little change when normalized to GAPDH in response to TGF-b, suggesting the difference in protein abundance could be a post-transcriptional effect. To further confirm this notion, we stably expressed human Skp2 (CCL64) were synchronized by contact inhibition and released into DME for 12 h in the presence or absence of 100 pM TGF-b. Cells were then washed with methionine and cysteine-free medium and labeled for 2 h with 1 mCi [
35 S]-Met per plate. After washing away the labeling medium, unlabeled methionine and cysteine were added at a concentration of 100 mg/ml and incubated for the indicated times. Cells were harvested in RIPA buffer, and p27
Kip1 was immunoprecipitated with an anti-p27
Kip1 antibody (Santa Cruz Biotech) and analysed by SDS-PAGE followed by autoradiography. (b) p27
Kip1 stability analysis using a cycloheximide chase experiment. Contact inhibited mink lung cells were released into growth medium in the presence or absence of 100 pM TGF-b for 12 h. Cycloheximide was added to the medium and cells were incubated for indicated times. Cell lysates prepared from different points of the cell cycle were analysed by Western blotting with an anti-p27 in mink lung cells using a bicistronic retroviral vector pREX-IRES-GFP (Liu et al., 2000a) . In this expression system, Skp2 and green fluorescence protein (GFP) were transcribed in a single mRNA, but translated independently due to the presence of an internal ribosomal entry site (IRES). If downregulation of Skp2 by TGF-b were a post-translational effect, we anticipated that ectopically expressed human Skp2 would be subjected to regulation similar to the endogenous Skp2. Mink lung cells stably expressing Skp2 were synchronized by contact inhibition and released into fresh medium in the presence or absence of TGF-b for the indicated times. As shown in Figure 3 , the recombinant human Skp2 is overexpressed and its accumulation is also cell cycle dependent. Again, treating cells with TGF-b decreases the levels of recombinant Skp2. As a control, we also measured levels of GFP transcribed from the same mRNA in this stable cell line. The levels of GFP are constant throughout the cell cycle and unaffected by TGF-b. This provides a strong argument that TGF-b selectively regulates the steady-state levels of endogenous and recombinant Skp2 in mink lung cells. These data suggest that a post-translation mechanism may be involved in controlling the steady-state levels of Skp2.
Destabilization of Skp2 by TGF-b
It has been shown previously that Skp2 undergoes proteasome-dependent degradation in serum-deprived human cells or in response to retinoic acid treatment in MCF7 breast cancer cells (Wirbelauer et al., 2000; Dow et al., 2001) . To determine whether TGF-b treatment destabilizes Skp2, we measured the stability of Skp2 protein. Since our antibody does not efficiently immunoprecipitate Skp2, we measured the stability of these two proteins using a cycloheximide chase experiment. As shown in Figure 4 , Skp2 was less stable in the presence of TGF-b. As a control, we also measured the stability of GFP that is synthesized from the same mRNA in the cells. GFP was very stable and there was no appreciable decrease during the chase period. These data suggest that Skp2 is destabilized upon TGF-b treatment and further support the notion that downregulation of Skp2 is largely a post-transcriptional effect.
TGF-b induced Skp2 degradation in vitro
To further define the biochemical mechanism of TGF-b induced Skp2 degradation, we analysed the Skp2 degradation in a cell-free degradation system. We have shown previously that cell extracts prepared from TGFb-stimulated mink lung cells can faithfully recapitulate the degradation behavior of proto-oncoprotein SnoN observed in cultured cells (Wan et al., 2001) . In vitro translated Skp2 was incubated with mink lung cell extracts prepared from TGF-b unstimulated and stimulated cells. As a control, in vitro translated GFP was also The levels of Skp2 were measured by Western blotting with an antiSkp2 antibody. As a control, the levels of GFP were also measured using an anti-GFP antibody. (b) The relative amounts of Skp2 remaining at the indicated times were quantified using NIH Image 1.62 software after densitometry scanning of the autorad in (a) and plotted Regulation of Skp2 proteolysis by TGF-b signaling W Wang et al added to the same cell extracts. As shown in Figure 5a , Skp2 is rapidly degraded in the extracts prepared from TGF-b-treated cells compared to the untreated cells. GFP is stable in both extracts (lanes 1-8). To determine whether degradation of Skp2 in vitro involves the proteasome, MG132 was added to the cell extracts along with Skp2. Degradation of Skp2 in TGF-b-treated cell extracts slows significantly by the presence of MG132 (Figure 5a , lanes 9-16). These data indicate that TGF-b can trigger degradation of Skp2 via a proteasome-dependent pathway in vitro.
TGF-b induced Skp2 degradation is mediated by Cdc34 in vitro
To dissect the proteolytic pathway required for degradation of Skp2, we set out to identify the potential ubiquitin conjugating enzyme (E2) that is involved in its destruction. Our approach was to add various dominantnegative E2s to the cell extracts and determine which dominant-negative E2 could inhibit Skp2 degradation in TGF-b-treated cell extracts. As shown in Figure 5b , addition of the wild-type Cdc34 or Ubc4 at 2.5 mM had little effect on Skp2 degradation in the TGF-b-treated cell extracts ( Figure 5b , lanes 1-12). In contrast, addition of dominant-negative Cdc34 dramatically inhibited Skp2 degradation, while addition of dominant-negative Ubc4 had much less effect, if any at all (Figure 5b, . The levels of GFP in the reaction mixture were unaffected by the addition of these recombinant enzymes. These experiments suggest that TGF-b-induced Skp2 degradation is likely mediated by ubiquitin conjugating enzyme Cdc34 and is consistent with the evidence for Skp2 degradation being mediated by a ubiquitin-dependent proteasome pathway.
Downregulation of Cks1 by TGF-b
Ubiquitination of p27 Kip1 requires the activity of Cks1 in addition to SCF complex. It has been shown that Cks1 may serve as an adapter to recruit phosphorylated p27
Kip1 to the SCF complex (Ganoth et al., 2001; Spruck et al., 2001; Sitry et al., 2002) . Simon et al. (1995) have shown previously that TGF-b represses transcription of Cks1, but the significance of the repression has not been established. To further investigate Cks1 regulation by TGF-b, we performed Northern blot analysis of Cks1 mRNA levels in mink lung cells and Hep3B cells. In agreement with previous observation, Cks1 mRNA is downregulated in mink lung cells (Figure 6a, lanes 1-7) . In addition, similar effects are also observed in Hep3B cells (Figure 6b, lanes 1-5) . Thus, TGF-b treatment causes a significant reduction in Cks1 expression in both mink and human cells. Ubiquitination of p27
Kip1 can be reconstituted in vitro using purified SCF Skp2 complex, E1 and E2 (Cdc34) Sutterluty et al., 1999; Tsvetkov et al., 1999; Winston et al., 1999) . If loss of Cks1 expression is responsible for stabilization of p27
Kip1
, we would expect that there would be a significant difference in p27
Kip1 ubiquitination between cell lysates prepared from TGF-b treated vs untreated cells. To demonstrate this, we performed a p27
Kip1 in vitro ubiquitination assay. Recombinant p27
Kip1 labeled with [
35 S]Met was phosphorylated by the recombinant Cdk2-cyclin E purified from Hi-Five insect cells prior to the addition to cell extracts prepared from the control or 16 h TGF-b treatment. As shown in Figure 7 , while p27
Kip1 is ubiquitinated in cell extracts that have not been treated with TGF-b (lane 4), there was no significant ubiquitination of p27
Kip1 in the treated cell extracts (lane 2). Addition of the recombinant Cks1 to the TGF-b treated extracts restores In contrast, addition of a Cks1 mutant (Cks1N45R) (Sitry et al., 2002) , which is defective in binding to Skp2 failed to restore p27 Kip1 ubiquitination. This result suggests that failure of p27 Kip1 ubiquitination is most likely due to the absence of Cks1 and that downregulation of Cks1 plays an important role in stabilization of p27
Kip1 in response to TGF-b. The observed effect of Cks1 on p27
Kip1 ubiquitination could be a global effect rather than SCF Skp2 specific. To rule out this scenario, we performed cyclin E ubiquitination experiment in vitro. Ubiquitination of cyclin E is catalysed by SCF Fbw7 (Koepp et al., 2001; Strohmaier et al., 2001) . As shown in Figure 7b , ubiquitination of cyclin E is Fbw7 dependent (lane 2 vs lane 3) as described previously (Koepp et al., 2001 ). This reaction is unaffected by the presence or absence of mink cell lysates treated with or without TGF-b (lanes 4 and 6). Nor does this reaction seem to be affected by the presence of recombinant Cks1 protein. Therefore, ubiquitination of cyclin E is not affected by the addition Fbw7 is unaffected by Cks1. Fbw7-dependent ubiquitination of cyclin E was reconstituted in vitro by incubating GST-cyclin ECdk2 complex with ATP, E1, Cdc34 (E2), MG132, ubiquitin aldehyde, an ATP regenerating system and Fbw7 generated by in vitro translation for 60 min at room temperature. Reaction mixtures were immunoblotted with an antibody against cyclin E (Santa Cruz). Lane 1, Cyclin E-Cdk2 complex purified from insect cells. Lane 2, Recombinant Fbw7 TNT lysate was incubated with Cyclin E-Cdk2. Lane 3, TNT lysate without Fbw7 was incubated with Cyclin E-Cdk2. Lane 4, Recombinant Fbw7 TNT lysate was incubated with Cyclin E-Cdk2 in the presence of TGF-b-treated cell extracts. Lane 5, Recombinant Fbw7 TNT lysate was incubated with Cyclin E-Cdk2 in the presence of TGF-b-treated cell extracts supplemented with 1 mg of recombinant Cks1. Lane 6, Recombinant Fbw7 TNT lysate was incubated with Cyclin E-Cdk2 in the presence of unstimulated cell extracts. Lane 7, Recombinant Fbw7 TNT lysate alone Kip1 ubiquitination is highly specific.
Regulation of Skp2 autoubiquitination by Cks1 and substrates
It has been proposed that autoubiquitination of the Fbox protein is important for the turnover and reassembly of the SCF complex (Zhou and Howley, 1998; Deshaies, 1999; Galan and Peter, 1999) . Skp2 can be autoubiquitinated and targeted to degradation by the proteasome (Wirbelauer et al., 2000) . Depletion of Cks1 in the presence of TGF-b should prevent p27
Kip1 from entering the E3 SCF Skp2 complex. We would expect that unoccupied SCF could ubiquitinate itself in the absence of the substrate. To test this hypothesis, we performed Skp2 self-ubiquitination assay using recombinant SCF complex prepared from insect cells. GST-Skp1, GSTCul1, His-Rbx and Flag-Skp2 were coexpressed in HiFive insect cells (Invitrogen). SCF Skp2 complexes were purified using glutathione-Sepharose (GSH) beads. Skp2 ubiquintination reactions were carried out by adding purified E1(BostonBiomed), E2(Cdc34), ubiquitin and methylated ubiquitin in the presence or absence of the substrate. The products of the reaction mixture were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The presence and the extent of Skp2 ubiquitin conjugates were analysed by anti-Skp2 immunoblotting. As shown in Figure 8a , high molecular weight Skp2 was detected when E1 and E2 were added to the reaction (lane 1). The slow migrating bands near the top of the gel are most likely the polyubiquitinated form of Skp2 because these bands are missing in the reactions where either E1 or E2 or ubiquitin were left out (lanes 6-8). Adding Cks1 alone or Cks1 plus unphosphorylated p27
Kip1 to the SCF Skp2 ubiquitination reaction has little effect on Skp2 ubiquitination. In contrast, when Cdk2-cyclin E complex, p27
Kip1 along with Cks1 were added together to the reaction, there is a significant decrease in Skp2 self-ubiquitination (lane 4). Interestingly, adding phosphorylated p27
Kip1 in the absence of Cks1 also resulted in a small reduction in Skp2 self-ubiquitination. This could be a result of low amounts of binding of the phosphorylated p27
Kip1 to SCF Skp2 in the absence of Cks1. To determine whether Skp2 self-ubiquitination can be inhibited by increasing concentrations of the Cdk2-cyclin E-p27-Cks1 complex, increasing amounts of this complex were added to the Skp2 self-ubiquitination reaction. As shown in Figure 8b , Skp2 self-ubiquitination is suppressed with increasing concentrations of the Cdk2-cyclin E-p27-Cks1 complex judging by the absence of high molecular weight Skp2-conjugates. As controls, we also added increasing concentrations of a mutant Cks1 (Cks1N45R) or Cks2, a closely related human homologue that shares 85% homology with Cks1, to the reactions. It has been shown previously that Cks1 but not Cks2 binds Skp2 in vitro and Cks1 N45-R mutation significantly impaired Skp2-Cks1 association (Sitry et al., 2002; Wang et al., 2003) . While addition of increasing amounts of Cks1N45R partially inhibits Skp2 self-ubiquitination, adding similar amounts of Cks2 has no effect. This result suggests inhibition of Skp2 selfubiqination is highly specific and correlates with association between Cks1 and Skp2. Thus, these data indicate that Skp2 is capable of self-ubiquitination in vitro. The extent of Skp2 self-ubiquitination is decreased when the substrate and Cks1 are available. Conversely, deficiency in Cks1 and in substrate availability likely increases Skp2 self-ubiquitination and, ultimately, turnover by the 26S proteasome.
Discussion
TGF-b exerts a strong antiproliferative effect on epithelial cells and causes cells to accumulate at the G1 phase of the cell cycle. Resistance to TGF-b is one of six hallmarks that differentiate normal and cancer cells (Hanahan and Weinberg, 2000) . The TGF-b signal transduction pathway is frequently altered in human tumor cells through mutations of essential signal transducers such as receptors, Smads or oncogenic activation that interferes with the normal function of the essential transducers (Massague et al., 2000; Liu et al., 2001 ). Compared to TGF-b-induced transcriptional paradigms, much less is known about the exact pathway by which TGF-b triggers cell growth arrest. Here we show that TGF-b signaling differentially regulates the stability of two important cell cycle players, p27
Kip1 and the F-box protein Skp2. TGF-b decreases levels of Skp2 at least in part by stimulating its proteolysis through a ubiquitin-mediated proteasome degradation pathway. This notion is further supported by our demonstration of accelerated Skp2 degradation in the cell-free extracts prepared from TGF-b-treated cells and the abrogation of Skp2 degradation in the presence of a dominant-negative ubiquitin conjugating enzyme Cdc34. Our results suggest that inhibition of Cdk2 kinase activity and cell cycle progression by TGFb could be a result of a stable association of p27
Kip1 with the Cdk2-cyclin E complex due to decreased levels of Skp2 and Cks1 expression triggered by TGF-b (Figure 9 ).
Numerous studies have established that the levels and stability of p27
Kip1 are highly significant prognostic markers for clinical progression of several types of human tumors. Reduced p27
Kip1 protein levels and increased p27
Kip1 degradation activity were found in many aggressive tumors and correlate with poor patient survival rate (Slingerland and Pagano, 2000) . Skp2 has been shown to be a rate-limiting component of the machinery that ubiquitinates and degrades p27 Kip1 Sutterluty et al., 1999) . In addition to p27 Kip1 , SCF Skp2 has also been shown to control the stability of Rb-related tumor suppressor p130 (Tedesco et al., 2002) . Therefore, high levels of Skp2 expression are expected to antagonize the levels of tumor suppressors, such as p27
Kip1 and p130. Consistent with this notion, Skp2 has been found to be overexpressed in Kip1 levels in human lymphoma (Gstaiger et al., 2001; Latres et al., 2001) . Therefore, aberrant expression of Skp2 could contribute to the development of human tumors. How do cells control Skp2 protein levels to ensure proper cell cycle regulation? Previous studies indicate that Skp2 levels are low in the G0 phase of the cell cycle, accumulate as cells enter the S phase of the cell cycle, and decline again when cells exit mitosis (Wirbelauer et al., 2000) . We demonstrated that dynamic changes in Skp2 protein levels are at least in part regulated by proteolysis. Data presented here are consistent with previous observations in that we saw a steady increase of Skp2 protein as cells enter the cell cycle (Figure 2a) . Furthermore, our data reveal that signal transduction pathways also influence the stability of Skp2 proteins. TGF-b can control cell cycle progression by limiting the abundance of this growth promoting protein. Therefore, we propose that Skp2 also functions to couple extrinsic control by growth factor to cell cycle progression in mammalian cells.
Our in vivo and in vitro data suggest that destabilization of Skp2 is primarily due to increased proteolysis. First, the steady-state levels of Skp2 mRNA show little change in response to TGF-b treatment. Secondly, ectopically expressed Skp2, using a heterologous retroviral LTR, is still subjected to this regulation. Skp2 was expressed using a bicistronic retroviral vector. Given that GFP and Skp2 were translated from the same mRNA, and GFP protein levels remain constant in the presence or absence of TGF-b, it is unlikely that changes in Skp2 levels are due to variations in steady-state levels of mRNA. Finally, in vitro translated recombinant Skp2 degradation is enhanced in cell extracts prepared from TGF-b-treated cells compared to the untreated control cells, and dominant-negative ubiquitin conjugating enzyme Cdc34 can abrogate Skp2 degradation in vitro. All of this evidence supports our hypothesis that Skp2 is a downstream target of the TGF-b signal transduction pathway.
Several lines of evidence have shown that the TGF-b signal transduction pathway regulates the ubiquitin proteasome degradation system and specifically targets SnoN (Stroschein et al., 1999; Sun et al., 1999; Wan et al., 2001) , Ski and HEF1 (Liu et al., 2000b) for destruction. In the case of SnoN, we and others have shown that TGF-b signaling promotes complex formation between Smad3 and CDH1 and recruits the anaphase promoting complex (APC) to ubiquitinate SnoN and targets for degradation Wan et al., 2001 ). Wrana and co-workers have shown additionally that TGF-b can induce assembly of a ubiquitin ligase complex containing an HECT domain protein Smurf2 and Smad2 or Smad7, which targets SnoN or the TGF-b type I receptor for degradation (Kavsak et al., 2000; Bonni et al., 2001) . Here, we show that both endogenous and recombinant Skp2 are targeted to destruction in response to TGF-b. Destabilization of Skp2 could be a result of direct recruitment of the APC to Skp2 by Smads in a fashion similar to SnoN degradation, an indirect result of TGF-b signaling, or both. At present we cannot distinguish between these possibilities, although our data are more consistent with an indirect effect as destabilization of Skp2 occurs only after considerable incubation with TGF-b (more than 12 h). APC-mediated degradation of SnoN occurs within an hour of TGF-b treatment (Stroschein et al., 1999; Sun et al., 1999) . Transcriptional repression of Cks1 and inhibition of Cdk2-cyclin E activity due to induction of cell cycle inhibitors such as p15 or p21 (Hannon and Beach, 1994; Datto et al., 1995; Reynisdottir and Massague, 1997) by TGF-b are probably prerequisites for Skp2 self-ubiquitination and subsequent degradation. Upregulation of CKI and downregulation of CKS in response to TGF-b could tip the balance towards inactivation of Cdk2-cyclin E activity. In this regard, negative regulation of the SCF Skp2 E3 ubiquitin ligase could serve as a reinforcement mechanism for commitment to a growth arrested state.
It has been shown previously that F-box proteins are themselves intrinsically unstable and are degraded by a ubiquitin-dependent pathway ( Zhou and Howley, 1998; Galan and Peter, 1999) . Ubiquitin-dependent degradation of F-box proteins allows rapid switching among multiple SCF complexes. We showed here that Skp2 is an unstable protein and is destabilized upon TGF-b signaling. The F-box protein Skp2 in the SCF Skp2 complex undergoes autoubiquitination in the absence of substrates and Cks1. Cks1 alone is insufficient for preventing Skp2 autoubiquitination. Significant decrease in Skp2 self-ubiquitination is observed only in the presence of Cks1, Cdk2-cylin E and p27
Kip1
. This result suggests that there is a competition between (Gstaiger et al., 2001; Latres et al., 2001 ). In addition, cyclin E is also overepressed in many tumor cells (Donnellan and Chetty, 1999) . It is possible that high levels of cyclin E and Cks1 may contribute to stabilization of Skp2 and excessive degradation of p27 Kip1 in many aggressive human cancers.
In summary, the data indicate that TGF-b signaling negatively regulates the SCF Skp2 E3 ubiquitin ligase through at least two distinct mechanisms. Transcriptional suppression of Cks1 expression and destabilization of Skp2 through a ubiquitin proteasome pathway may contribute directly to enhanced stability of p27 Kip1 in TGF-b-treated cells. This regulation may be one of the important molecular mechanisms by which TGF-b induces growth arrest in epithelial cells.
Material and methods
Cell lines, transfection and infection
Mv1Lu mink lung epithelial cells CCL64, BOSC23 and 293T cell lines were maintained in DMEM medium supplemented with L-glutamine, penicillin, streptomycin and 10% fetal bovine serum (GIBCO/BRL). 293T cells were transfected using Fugene 6 (Roche). Retroviruses were harvested 48, 72 and 96 h post-transfection and frozen at À801C prior to infection. Retroviral infection and cell sorting were described previously (Liu et al., 1997 (Liu et al., , 2000a .
DNA expression constructs and recombinant proteins
Mammalian expression vectors pcDNA3-Skp2 and Skp2DF were kindly provided by Drs Pagano and Pengbo Zhou. Human Skp2 and Skp2DF were subcloned into pREX-IRES-GFP vector (Liu et al., 1997 (Liu et al., , 2000a and stably expressed in mink lung cells using retroviral mediated gene transfer. Mammalian pSG5 vector, pSG5-Cdc34 and pSG5-Cdc34DN were kindly provided by Dr Plon. UBC4 expression vector was kindly provided by Dr Pagano. Dominant-negative CDC34 (CDC34DN) and UBC4(UBC4DN) were constructed by use of the Quikchange site-specific mutagenesis kit (Stratagene). Both wild-type and dominantnegative E2s were subcloned into the pQE30 expression vector and recombinant proteins were purified over Ninitrilotriacetic (NTA) resin (Qiagen). The protein eluates were further purified using a Superdex200 gel filtration column (Amersham Biosciences). The fractions corresponding to Cdc34 dimers were collected and stored in QA buffer (20 mM Tris-HCl pH 7.7, 100 mM KCl, 0.1 mM CaCl 2 1 mM MgCl2 and 1 mM DTT) plus 10% glycerol.
Recombinant baculoviruses expressing GST-Skp1, CUL1, Roc1, Flag-Skp2, GST-Cyclin E and Cdk2 have been described previously (Winston et al., 1999) . Baculoviruses were amplified in Sf9 cells and coinfections were carried out in HiFive cells (Invitrogen). SCF complex and Cdk2-cyclin E were purified using GST affinity chromatography and stored in QA buffer at À801C.
Flow cytometry and cell cycle analysis
Mink lung cells were synchronized by density arrest and released into fresh DME medium after split as described previously (Laiho et al., 1990) . Cells were trypsinized and pelleted by centrifugation. After washing with PBS, cells were fixed in 70% ice-cold ethanol overnight at 41C. To stain the samples, cells were pelleted again by centrifugation and vortexed to resuspend in residual ethanol. A measure of 1 ml of PI staining solution (50 mg/ml PI, RNaseA in PBS and glucose) was added to each sample and gently vortexed. Samples were incubated at room temperature for more than 1 h and analysed by FACScan (Becton Dickinson).
Pulse chase and protein stability measurement
Cells were incubated in methionine-free medium for 30 min prior to labeling. The medium was then exchanged with fresh medium containing 1mCi of [ 35 S]methionine and incubated for 2 h. Cells were rinsed twice with PBS and once with chasing medium containing 100 mg/ml cold methionine and cystein) and left in chasing medium for the indicated times. Cells were then lysed in RIPA buffer and protein lysates were subjected to immunoprecipitation analysis using the indicated antibodies. Protein stability analysis was also performed using cycloheximide (10 mg/ml) to inhibit new protein synthesis and measure the amount of protein present in the cell lysates over the indicated periods of time. Cells were treated with or without 100 pM TGF-b in the presence of cycloheximide for the indicated times and lysed with RIPA buffer. Western blot analyses were then performed with the indicated antibodies.
Antibodies and immunoblotting analysis
Protein extracts were prepared from cell lines by lysing equal numbers of cells directly in cell lysis buffer (50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM EDTA, 1% NP40, 15% glycerol). The protein concentrations were measured by Bradford assay (Biorad). Samples were resolved on 8 or 12% SDS-PAGE and electrophoretically transferred to nitrocellulose. Western blot analysis was performed using the HA1.1 monoclonal antibody, anti-GFP (Covance), Skp2 (Santa Cruz), anti-p27 Kip1 (Santa Cruz) or anti-Cdc34 (Transduction Laboratory) antibodies. The proteins were detected using HRP conjugated goat-anti-mouse or rabbit secondary antibody (Amersham) with an ECL WesternDura detection kit (Pierce).
Northern blot analysis
A RNeasy kit (Qiagen) was used to prepare total cellular RNA following the manufacturer's instructions. RNA samples (20 mg of each) were electrophoresed on a 1% agarose-formaldehyde gel and were blotted to a Nytran membrane (Amersham). Radiolabeled probes were prepared by a Rediprim labeling kit (Amersham) and hybridized overnight at 42 o C with the membrane in an Ultrahyb solution (Ambion).
Preparation of mink lung epithelial cell extracts
Mink lung epithelial cells were cultured on 150-mm plates in DME medium supplemented with 10% FBS in 5% CO 2 and grown to 80% confluence. A total of plates were either treated with 100 pM TGF-b (R&D system) or left untreated for 12 h. After 12 h, cells were washed with PBS and harvested by scraping. Cells (ca. 1 Â 10 8 ) were resuspended in 500 ml hypotonic buffer (20 mM HEPES pH 7.5, 5 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 1 Â protease cocktail (Roche)) and an energy regeneration system for 30 min to allow the cells to swell. Cells were lysed according to the procedure described previously and aliquoted for storage at -80 o C in preparation for the protein degradation assay.
Protein degradation assay
The wild-type and Skp2 mutant proteins were prepared and labeled by a coupled in vitro transcription and translation system (TNT) (Promega) in the presence of 35 S-labeled methionine (Amersham). Reaction mixtures containing 10 ng of 35 S-labeled protein, 1.25 mg/ml ubiquitin (Sigma), 0.1 mg/ml of cycloheximide, energy regeneration system (Murray, 1991) , and approximately 10 mg of mink lung cell extract were incubated at room temperature. Aliquots were removed at indicated time points and the reaction was terminated by the addition of SDS sample buffer. Samples were analysed by 12% SDS-PAGE. Degradation of Skp2 was determined by a PhosphorImager or autoradiography.
p27
kip1 and Skp2 ubiquitination assay Recombinant p27 prepared from E.coli was phosphorylated with purified 0.5 mM Cdk2-cyclin E complex in the presence of 0.5 mM ATP, and an energy regeneration system prior to the addition to the ubiquitination reaction mixture. A typical reaction mixture contains 2 ml of 35 S-labeled p27, 0.2 mM SCF complex, 100 ng of E1 (Boston Biochem, Inc.), 5 mg of recombinant Cdc34, 6 mg of ubiquitin (Sigma), 5 pmol of ubiquitinaldehyde (CalBiochem), 1 mg/ml of methylated ubiquitin (Boston Biochem, Inc.), 1 mg/ml of soybean trypsin inhibitor, 1 ml of 10XATP regeneration system (20 mM HEPES, pH 7.4, 10 mM ATP, 10 mM MgOAc, 300 mM creatine phosphate, 0.5 mg/ml creatine phosphokinase) in 10 ml of reaction buffer (40 mM MgOAc, 5 mM DTT and 1 mM PMSF). Reaction mixtures were incubated at 301C for 1 h and stopped by adding 1 Â SDS sample buffer. Samples were subjected to SDS-PAGE analysis and exposed to PhosphorImager analysis (Molecular Dynamics). For ubiquitination of p27
Kip1 in cell extracts, 1 mM of okadaic acid was included in the reaction to prevent dephosphorylation of p27
Kip1 (Montagnoli et al., 1999) . Skp2 self-ubiquitination assays were performed under the same conditions as the p27
Kip1 ubiquitination reaction except nonradiolabeled substrate was used, and the reaction mixtures were analysed by Western blotting with indicated antibodies. Ubiquitination of cyclin E was performed as described previously (Koepp et al., 2001) .
